HER2, HER3, and TROP2: Diagnostic Testing and Treatment Implications in Breast, GI, and Lung Cancers

Download All
Review the latest expert guidance on assessing and targeting HER2, HER3, and TROP2 in the metastatic setting for diverse malignancies with on-demand Webcasts and downloadable slides from CCO’s live Webinars, along with expert-authored commentaries, a pocket guide on best practices for testing, and brief Medical Minute slide/audio presentations for oncologists and pathologists.
Mark D. Pegram, MD
Program Director
Michael F. Press, MD, PhD
Program Director
Kimberly Allison, MD
Daniel Catenacci, MD
Axel Grothey Headshot
Axel Grothey, MD
Sara Hurvitz, MD, FACP
Yelena Y. Janjigian, MD
Sandip P. Patel, MD
Mark D. Pegram, MD
Michael F. Press, MD, PhD
Manish A. Shah, MD
person default
Conor Ernst Steuer, MD

On-Demand Webcasts

Hear how the experts test for HER2, HER3, and TROP2 in metastatic breast cancer, then learn how to optimally leverage established and emerging therapies targeting these biomarkers.

Mark D. Pegram, MD
Program Director
Michael F. Press, MD, PhD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits ABIM MOC: maximum of 1.25 Medical Knowledge MOC point(s) ABPath MOC: maximum of 1.25 Lifelong Learning (Part II) and Self-Assessment Module (SAM) point(s) Released: September 10, 2020 Expired: September 9, 2021

In this interactive on-demand Webcast, gain expert insights into current best practices and emerging data surrounding the use of HER2-, HER3-, and TROP2-targeted agents for treating metastatic breast cancer.

Mark D. Pegram, MD
Program Director
Physicians: maximum of 0.75 AMA PRA Category 1 Credits ABIM MOC: maximum of 0.75 Medical Knowledge MOC point(s) ABPath MOC: maximum of 0.75 Lifelong Learning (Part II) and Self-Assessment Module (SAM) point(s) Released: September 29, 2020 Expired: September 28, 2021

Watch this on-demand Webcast to gain expert perspectives on best practices and emerging data informing pathologic assessment of HER2 status and leveraging of HER2-targeted agents for gastrointestinal malignancies.

Mark D. Pegram, MD
Program Director
Michael F. Press, MD, PhD
Program Director
Axel Grothey Headshot Axel Grothey, MD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits ABIM MOC: maximum of 0.75 Medical Knowledge MOC point(s) ABPath MOC: maximum of 0.75 Lifelong Learning (Part II) and Self-Assessment Module (SAM) point(s) Released: November 2, 2020 Expired: November 1, 2021

Watch this on-demand Webcast for an expert panel discussion of pathologic testing and targeted therapy surrounding the HER2, HER3, and TROP2 biomarkers in metastatic breast and GI cancers.

Mark D. Pegram, MD
Program Director
Michael F. Press, MD, PhD
Program Director
Axel Grothey Headshot Axel Grothey, MD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits ABIM MOC: maximum of 0.75 Medical Knowledge MOC point(s) ABPath MOC: maximum of 0.75 Lifelong Learning (Part II) and Self-Assessment Module (SAM) point(s) Released: December 17, 2020 Expired: December 16, 2021

Downloadable Slidesets

Download this short summary slideset of key takeaway points from a live presentation on HER2 testing and how this can inform treatment in metastatic breast cancer.

Mark D. Pegram, MD
Program Director
Michael F. Press, MD, PhD
Released: July 30, 2020

Download this short summary slideset of key takeaway points from a live presentation on approved and emerging investigational HER2-, HER3-, and TROP2-targeted therapies for metastatic breast cancer.

Mark D. Pegram, MD
Program Director
Released: August 24, 2020

Download this short summary slideset of key takeaway points from a live presentation on HER2 testing and targeted therapy in advanced gastrointestinal cancers.

Axel Grothey Headshot Axel Grothey, MD Michael F. Press, MD, PhD Released: September 30, 2020

Download this short summary slideset of key takeaway points from a live presentation on HER2, HER3, and TROP2 testing and targeted therapy in advanced breast and gastrointestinal cancers.

Axel Grothey Headshot Axel Grothey, MD Mark D. Pegram, MD Michael F. Press, MD, PhD Released: October 30, 2020

Download this slideset for expert perspectives on key nuances of HER2 testing in metastatic breast cancer and how test results inform HER2-targeted therapy decisions.

Mark D. Pegram, MD
Program Director
Michael F. Press, MD, PhD
Released: July 30, 2020

Download this slideset to review key data and expert perspectives on approved and emerging investigational HER2-, HER3-, and TROP2-targeted therapies for metastatic breast cancer.

Mark D. Pegram, MD
Program Director
Released: August 21, 2020

Download this slideset to review key data and expert perspectives on HER2 testing and targeted therapy in advanced gastrointestinal cancers.

Axel Grothey Headshot Axel Grothey, MD Michael F. Press, MD, PhD Released: September 25, 2020

Download this slideset for an expert overview of HER2 testing in metastatic breast and GI cancers and the use novel HER2, HER3, and TROP2-targeted therapeutics for these malignancies.

Mark D. Pegram, MD
Program Director
Axel Grothey Headshot Axel Grothey, MD Michael F. Press, MD, PhD
Released: October 29, 2020

Downloadable Summary Resource

Download this PDF summarizing key points in HER2, HER3, and TROP2 testing and targeted therapy for patients with breast, GI, and lung cancers.

Mark D. Pegram, MD
Program Director
Michael F. Press, MD, PhD
Released: July 30, 2020

ClinicalThought

What is new in testing for HER2 in breast cancer and beyond? How might newly approved and emerging therapies targeting HER2, HER3, and TROP2 affect your practice? Here’s my take.

Mark D. Pegram, MD
Program Director
Released: July 23, 2020

How could emerging therapies targeting HER2, HER3, and TROP2 affect management of patients with NSCLC? Here are my thoughts on promising agents and potential clinical implications.

Sandip P. Patel, MD Released: November 23, 2020

The approval of trastuzumab deruxtecan provides another treatment option for patients with HER2-positive advanced gastric cancers. Review this expert commentary on how to incorporate this agent into your practice.

Yelena Y. Janjigian, MD Released: February 15, 2021

Medical Minutes

This short activity provides expert insight on optimal use of recently approved HER2- and TROP2-targeted agents for patients with metastatic breast cancer, focusing on neratinib, trastuzumab deruxtecan, tucatinib, and sacituzumab govitecan.

Mark D. Pegram, MD
Program Director
Sara Hurvitz, MD, FACP Michael F. Press, MD, PhD
Physicians: maximum of 0.25 AMA PRA Category 1 Credits ABIM MOC: maximum of 0.25 Medical Knowledge MOC point(s) Released: November 9, 2020 Expired: November 8, 2021

This short activity provides expert insight into questions frequently asked by clinicians surrounding HER2 testing in metastatic breast cancer.

Mark D. Pegram, MD
Program Director
Kimberly Allison, MD Michael F. Press, MD, PhD
Physicians: maximum of 0.25 AMA PRA Category 1 Credits ABIM MOC: maximum of 0.25 Medical Knowledge MOC point(s) Released: December 10, 2020 Expired: December 9, 2021

This short activity provides expert insights into best practices in key facets of HER2 testing in metastatic breast cancer and discusses optimal communication between pathologists and the multidisciplinary care team in the community setting.

Mark D. Pegram, MD
Program Director
Michael F. Press, MD, PhD
Program Director
Kimberly Allison, MD
Physicians: maximum of 0.25 AMA PRA Category 1 Credits ABIM MOC: maximum of 0.25 Medical Knowledge MOC point(s) Released: December 9, 2020 Expired: December 8, 2021

This short activity provides expert insights into HER2 testing for advanced gastrointestinal cancers and discusses current and emerging HER2- and HER3-targeted therapies for patients with these malignancies.

Mark D. Pegram, MD
Program Director
Michael F. Press, MD, PhD
Program Director
Manish A. Shah, MD
Physicians: maximum of 0.25 AMA PRA Category 1 Credits ABIM MOC: maximum of 0.25 Medical Knowledge MOC point(s) Released: January 8, 2021 Expired: January 7, 2022

This focused activity provides an expert’s perspective on the most clinically relevant data for approved and investigational therapies targeting HER2 and HER3 in advanced gastroesophageal and colorectal cancers.

Mark D. Pegram, MD
Program Director
Michael F. Press, MD, PhD
Program Director
Daniel Catenacci, MD
Physicians: maximum of 0.5 AMA PRA Category 1 Credits ABIM MOC: maximum of 0.5 Medical Knowledge MOC point(s) Released: May 27, 2021 Expired: May 26, 2022

This short interactive virtual presentation provides expert insights into emerging antibody–drug conjugates targeting HER2, HER3, and TROP2 in patients with NSCLC, including the most recent data from major conferences.

Mark D. Pegram, MD
Program Director
Michael F. Press, MD, PhD
Program Director
person default Conor Ernst Steuer, MD
Physicians: maximum of 0.25 AMA PRA Category 1 Credits ABIM MOC: maximum of 0.25 Medical Knowledge MOC point(s) Released: May 7, 2021 Expired: May 6, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue